On 2/27/2021 8:34 AM, Taxed and Spent wrote:
> On 2/27/2021 8:20 AM, Boron Elgar wrote:
>> On Sat, 27 Feb 2021 08:06:37 -0800, Taxed and Spent
>> > wrote:
>>
>>> On 2/27/2021 8:00 AM, Graham wrote:
>>>> On 2021-02-27 6:04 a.m., Snag wrote:
>>>>> On 2/26/2021 11:03 PM, Graham wrote:
>>>>>> On 2021-02-26 9:45 p.m., Snag wrote:
>>>>>>
>>>>>>>>
>>>>>>>
>>>>>>> Â*Â* So "it's for my own good" makes it OK . I wouldn't find it so
>>>>>>> annoying if this were truly the killer pandemic they claimed . Yes ,
>>>>>>> those with compromised health were hardest hit . But the fact remains
>>>>>>> that this thing has a fatality rate of .03-.05% , down in the weeds
>>>>>>> with the common cold and seasonal flu . Another factor that screams
>>>>>>> fraud and conspiracy is that hydroxychloroquine all at once is a
>>>>>>> viable treatment - after hundreds of thousands that could have been
>>>>>>> treated died while "they" were screaming no no no it'll kill you .
>>>>>>
>>>>>> Wow! So you know more than all those research scientists that did
>>>>>> careful studies and proved that what you write is a load of codswallop!
>>>>>> I'm surprised that Fauci hasn't contacted you with a job offer!
>>>>>>
>>>>>
>>>>> Â* I know that other trials has great results , and were quashed by the
>>>>> liberal media .
>>>>
>>>> Oh! Of course it's ALWAYS the liberal media.
>>>>
>>>> I know that there were doctors and researchers that were
>>>>> canceled for not spouting the party line .Â* You really should consider
>>>>> watching/reading something other than mainstream media .
>>>>
>>>> Liek FuxNews and QAnon?
>>>> FFS, take your head out of your arse!
>>>>
>>>
>>> "In this retrospective observational study of SARS-CoV-2 infected
>>> non-hospitalized patients hydroxychloroquine exposure was associated
>>> with a decreased rate of subsequent hospitalization. Additional
>>> exploration of hydroxychloroquine in this mildly symptomatic outpatient
>>> population is warranted."
>>>
>>> https://bmcinfectdis.biomedcentral.c...79-021-05773-w
>>
>> Open access published - for a fee. Try again.
>>
>
> no fee for me.
>


Our findings in the outpatient setting are in conflict with prior
observational studies conducted among hospitalized patients potentially
highlighting differences in effect based on the severity of disease
[27]. Following an initial infection by SARS-CoV-2 resulting in attack
of alveolar epithelial cells patients may develop a hyper-inflammatory
state characterized by activation of the innate immune system and
release of pro-inflammatory cytokines and chemokines. Patients who
experience this "cytokine storm progress rapidly to respiratory failure
and multi-organ failure [28,29,30,31]. In these hospitalized patients
the weak anti-inflammatory effects of hydroxychloroquine may be
insufficient to block the cytokine cascade, whereas more potent
immunosuppressive agents such as dexamethasone and tocilizumab have been
associated with beneficial effects [21, 32, 33].

By contrast, hydroxychloroquine has anti-viral effects, decreasing
SARS-CoV-2 viral load, and thus may be more suited in preventing the
significant tissue damage needed to incite the hyper-inflammatory state
[5, 34]. This would position hydroxychloroquine earlier in the clinical
course, at the time of early infection, prior to hospitalization need [35].

On Sat, 27 Feb 2021 08:37:06 -0800, Taxed and Spent
> wrote:

>On 2/27/2021 8:34 AM, Taxed and Spent wrote:

>>>>
>>>> "In this retrospective observational study of SARS-CoV-2 infected
>>>> non-hospitalized patients hydroxychloroquine exposure was associated
>>>> with a decreased rate of subsequent hospitalization. Additional
>>>> exploration of hydroxychloroquine in this mildly symptomatic outpatient
>>>> population is warranted."
>>>>
>>>> https://bmcinfectdis.biomedcentral.c...79-021-05773-w
>>>
>>> Open access published - for a fee. Try again.
>>>
>>
>> no fee for me.
>>
>
>
>Our findings in the outpatient setting are in conflict with prior
>observational studies conducted among hospitalized patients potentially
>highlighting differences in effect based on the severity of disease
>[27]. Following an initial infection by SARS-CoV-2 resulting in attack
>of alveolar epithelial cells patients may develop a hyper-inflammatory
>state characterized by activation of the innate immune system and
>release of pro-inflammatory cytokines and chemokines. Patients who
>experience this ‘cytokine storm’ progress rapidly to respiratory failure
>and multi-organ failure [28,29,30,31]. In these hospitalized patients
>the weak anti-inflammatory effects of hydroxychloroquine may be
>insufficient to block the cytokine cascade, whereas more potent
>immunosuppressive agents such as dexamethasone and tocilizumab have been
>associated with beneficial effects [21, 32, 33].
>
>By contrast, hydroxychloroquine has anti-viral effects, decreasing
>SARS-CoV-2 viral load, and thus may be more suited in preventing the
>significant tissue damage needed to incite the hyper-inflammatory state
>[5, 34]. This would position hydroxychloroquine earlier in the clinical
>course, at the time of early infection, prior to hospitalization need [35].


Let's apply a bit of logic here.....can you provide a pointer to any
Covid 19 medication protocol that includes hydroxychloroquine? We have
over 500,000 people dead in this country. We have had over 29 million
with positive tests. Do you really think there is some reason that
hydroxychloroquine is not part of best practices treatment of Covid
patients?

Were this an effective medication for it, it would gladly be used, not
laughed at.

Boron Elgar wrote:

> On Sat, 27 Feb 2021 08:37:06 -0800, Taxed and Spent
> > wrote:
>
> > On 2/27/2021 8:34 AM, Taxed and Spent wrote:
>
> > > > >
> >>>> "In this retrospective observational study of SARS-CoV-2 infected
> >>>> non-hospitalized patients hydroxychloroquine exposure was
> associated >>>> with a decreased rate of subsequent hospitalization.
> Additional >>>> exploration of hydroxychloroquine in this mildly
> symptomatic outpatient >>>> population is warranted."
> > > > >
> >>>>
>
https://bmcinfectdis.biomedcentral.c...79-021-05773-w
> > > >
> >>> Open access published - for a fee. Try again.
> > > >
> >>
> >> no fee for me.
> >>
> >
> >
> > Our findings in the outpatient setting are in conflict with prior
> > observational studies conducted among hospitalized patients
> > potentially highlighting differences in effect based on the
> > severity of disease [27]. Following an initial infection by
> > SARS-CoV-2 resulting in attack of alveolar epithelial cells
> > patients may develop a hyper-inflammatory state characterized by
> > activation of the innate immune system and release of
> > pro-inflammatory cytokines and chemokines. Patients who experience
> > this ‘cytokine storm’ progress rapidly to respiratory failure and
> > multi-organ failure [28,29,30,31]. In these hospitalized patients
> > the weak anti-inflammatory effects of hydroxychloroquine may be
> > insufficient to block the cytokine cascade, whereas more potent
> > immunosuppressive agents such as dexamethasone and tocilizumab have
> > been associated with beneficial effects [21, 32, 33].
> >
> > By contrast, hydroxychloroquine has anti-viral effects, decreasing
> > SARS-CoV-2 viral load, and thus may be more suited in preventing
> > the significant tissue damage needed to incite the
> > hyper-inflammatory state [5, 34]. This would position
> > hydroxychloroquine earlier in the clinical course, at the time of
> > early infection, prior to hospitalization need [35].
>
>
> Let's apply a bit of logic here.....can you provide a pointer to any
> Covid 19 medication protocol that includes hydroxychloroquine? We have
> over 500,000 people dead in this country. We have had over 29 million
> with positive tests. Do you really think there is some reason that
> hydroxychloroquine is not part of best practices treatment of Covid
> patients?
>
> Were this an effective medication for it, it would gladly be used, not
> laughed at.

+1

Taxed and Spent wrote:

> On 2/27/2021 8:34 AM, Taxed and Spent wrote:
> > On 2/27/2021 8:20 AM, Boron Elgar wrote:
> >> On Sat, 27 Feb 2021 08:06:37 -0800, Taxed and Spent
> >> > wrote:
> > >
> >>> On 2/27/2021 8:00 AM, Graham wrote:
> >>>> On 2021-02-27 6:04 a.m., Snag wrote:
> >>>>> On 2/26/2021 11:03 PM, Graham wrote:
> >>>>>> On 2021-02-26 9:45 p.m., Snag wrote:
> > > > > > >
> > > > > > > > >
> > > > > > > >
> >>>>>>> Â*Â* So "it's for my own good" makes it OK . I wouldn't find
> it so >>>>>>> annoying if this were truly the killer pandemic they
> claimed . Yes , >>>>>>> those with compromised health were hardest
> hit . But the fact remains >>>>>>> that this thing has a fatality
> rate of .03-.05% , down in the weeds >>>>>>> with the common cold and
> seasonal flu . Another factor that screams >>>>>>> fraud and
> conspiracy is that hydroxychloroquine all at once is a >>>>>>> viable
> treatment - after hundreds of thousands that could have been >>>>>>>
> treated died while "they" were screaming no no no it'll kill you .
> > > > > > >
> >>>>>> Wow! So you know more than all those research scientists that
> did >>>>>> careful studies and proved that what you write is a load
> of codswallop! >>>>>> I'm surprised that Fauci hasn't contacted you
> with a job offer!
> > > > > > >
> > > > > >
> >>>>> Â* I know that other trials has great results , and were
> quashed by the >>>>> liberal media .
> > > > >
> >>>> Oh! Of course it's ALWAYS the liberal media.
> > > > >
> >>>> I know that there were doctors and researchers that were
> >>>>> canceled for not spouting the party line .Â* You really should
> consider >>>>> watching/reading something other than mainstream media
> .
> > > > >
> >>>> Liek FuxNews and QAnon?
> >>>> FFS, take your head out of your arse!
> > > > >
> > > >
> >>> "In this retrospective observational study of SARS-CoV-2 infected
> >>> non-hospitalized patients hydroxychloroquine exposure was
> associated >>> with a decreased rate of subsequent hospitalization.
> Additional >>> exploration of hydroxychloroquine in this mildly
> symptomatic outpatient >>> population is warranted."
> > > >
> >>>
>
https://bmcinfectdis.biomedcentral.c...79-021-05773-w
> > >
> >> Open access published - for a fee. Try again.
> > >
> >
> > no fee for me.
> >
>
>
> Our findings in the outpatient setting are in conflict with prior
> observational studies conducted among hospitalized patients
> potentially highlighting differences in effect based on the severity
> of disease [27]. Following an initial infection by SARS-CoV-2
> resulting in attack of alveolar epithelial cells patients may develop
> a hyper-inflammatory state characterized by activation of the innate
> immune system and release of pro-inflammatory cytokines and
> chemokines. Patients who experience this "cytokine storm progress
> rapidly to respiratory failure and multi-organ failure [28,29,30,31].
> In these hospitalized patients the weak anti-inflammatory effects of
> hydroxychloroquine may be insufficient to block the cytokine cascade,
> whereas more potent immunosuppressive agents such as dexamethasone
> and tocilizumab have been associated with beneficial effects [21, 32,
> 33].
>
> By contrast, hydroxychloroquine has anti-viral effects, decreasing
> SARS-CoV-2 viral load, and thus may be more suited in preventing the
> significant tissue damage needed to incite the hyper-inflammatory
> state [5, 34]. This would position hydroxychloroquine earlier in the
> clinical course, at the time of early infection, prior to
> hospitalization need [35].

Date site